Condition: Multiple Sclerosis · Sponsor: Hoffmann-La Roche
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS). The study consists of two treatment phases: a dose-escalation and dose-continuation phase. Participants will receive single ascending doses of ocrelizumab SC during an initial dose-escalation phase, with the option to continue treatment with the selected dose of ocrelizumab SC in the dose-continuation phase.
This description comes directly from the study's public registry record.
Reference Study ID Number: WN45319 https://forpatients.roche.com/ · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Always discuss trial participation with your own doctor first.
| Profound Research, LLC | Carlsbad, California, United States | Active Not Recruiting |
| Neurology Associates, PA | Maitland, Florida, United States | Active Not Recruiting |
| University of South Florida | Tampa, Florida, United States | Active Not Recruiting |
| Shepherd Center Inc. | Atlanta, Georgia, United States | Active Not Recruiting |
| John Hopkins University School of Medicine | Baltimore, Maryland, United States | Active Not Recruiting |
| Hope Neurology | Knoxville, Tennessee, United States | Active Not Recruiting |
| Instituto de Neurologia de Curitiba | Curitiba, Paraná, Brazil | Active Not Recruiting |
| Centro de Pesquisas Clinicas | São Paulo, São Paulo, Brazil | Active Not Recruiting |
| Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C. | Guadalajara, Jalisco, Mexico | Recruiting |
| Inovacion y Desarrollo en ciencias de la salud | Mexico City, Mexico CITY (federal District), Mexico | Active Not Recruiting |
| Nottingham University Hospitals NHS Trust | Nottingham, United Kingdom | Active Not Recruiting |
| Morriston Hospital | Swansea, United Kingdom | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07667322